drugset

drugset / Trial / NCT05896124

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

NCT05896124 ↗

Phase 2 Active not recruiting 75 enrolled Cascade Pharmaceuticals, Inc

RandomizedParallel-groupDouble-blindTreatment

Summary

A phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis).

Timeline

Start: 2023-08-07
Primary completion: 2025-12-31
Completion: 2026-03-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CS0159	Unknown	2 mg	Oral

Indications